Milestone Pharmaceuticals
MIST
31 hedge funds and large institutions have $111M invested in Milestone Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 6 closing their positions.
201% more capital invested
Capital invested by funds: $36.9M → $111M (+$74.2M)
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
29% more funds holding
Funds holding: 24 → 31 (+7)
23.06% more ownership
Funds ownership: 39.6% → 62.66% (+23%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $523K
Top Buyers
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.3M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$12.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$4.84M |
| 4 |
O
OrbiMed
New York
|
+$2.77M |
| 5 |
Millennium Management
New York
|
+$2.21M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $13K | +$12.2K | +1,700 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $7K | -$10.8K | -1,507 | -62% |
|
|
28
Millennium Management
New York
| $2.25K | +$2.21M | +307,754 | New |
|
|
CFGS
29
Concourse Financial Group Securities
Birmingham,
Alabama
| $2K | – | – | – |
|
|
KPF
30
K2 Principal Fund
Toronto,
Ontario, Canada
| – | -$642K | -169,730 | Closed |
|
|
SSA
31
Schonfeld Strategic Advisors
New York
| – | -$125K | -33,200 | Closed |
|
|
SAMH
32
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
| – | -$98K | -26,000 | Closed |
|
33
Two Sigma Advisers
New York
| – | -$79K | -20,900 | Closed |
|
|
SFS
34
Sowell Financial Services
North Little Rock,
Arkansas
| – | -$30K | -8,000 | Closed |
|
35
BlackRock
New York
| – | -$18K | -4,717 | Closed |
|
36
Simplex Trading
Chicago,
Illinois
| – | +$423 | +59 | New |
|
MIST Hedge Fund Activity: Q3 2020 in Review
31 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2020, worth a combined $111M — up 201% from $36.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MIST positions and 6 closed out — a net gain of 7 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $17.3M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $642K sold.
- 31 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2020, up from 24 in Q2 2020.
- Funds reported $111M of Milestone Pharmaceuticals stock for Q3 2020, up 201% quarter-over-quarter.
- 13 funds opened new Milestone Pharmaceuticals positions in Q3 2020 and 6 closed out, a net change of +7 holders.
- The largest Milestone Pharmaceuticals buyer in Q3 2020 was RA Capital Management, an estimated $17.3M added.
- The largest Milestone Pharmaceuticals seller in Q3 2020 was K2 Principal Fund, an estimated $642K sold.
Based on aggregated 13F filings for Q3 2020.